Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Twist Bioscience Corp(TWST)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TWST
11/06/2026: TWST (3-star) is currently NOT-A-BUY. Pass it for now.
Twist Bioscience Corp is a life sciences company known for its proprietary silicon-based platform that manufactures synthetic DNA at scale. The company serves as a vital supplier for researchers in biotechnology and pharmaceutical drug discovery, offering everything from synthetic genes to targeted sequencing tools. Its main investment appeal lies in the potential for significant growth as genomic research and biologics adoption expand. However, investors must consider that the company is currently not consistently profitable and faces intense competition from larger, well-capitalized life science tools firms. Twist is best suited for growth-oriented investors, and market participants should monitor its path to margin improvement and progress in its biopharma services segment.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth synthetic biology space with a scalable technology platform. |
| Momentum investor | Mixed fit | The stock can exhibit strong momentum based on biotech sentiment, but is subject to high volatility. |
| Value investor | Weak fit | The company is not yet consistently profitable, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Twist does not pay a dividend as it prioritizes growth-stage capital reinvestment. |
| Low-risk investor | Weak fit | High price volatility and lack of profitability make this unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to biotechnology market sentiment and macroeconomic shifts. |
| Valuation risk | Medium / high | High growth expectations can lead to significant valuation swings based on small changes in growth forecasts. |
| Competition risk (Life Sciences Tools) | High | Competition from large, well-capitalized companies in sequencing and synthesis poses a constant threat. |
| Business quality | Medium | While the technology is innovative, the company is still in a phase of establishing long-term sustainable margins. |
| Dividend income | Low / none | There is no income component for shareholders. |
| Execution risk | Medium / high | The company must continue to scale its manufacturing and prove the viability of newer business lines. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 33.63% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.01B USD | Price to earnings Ratio - | 1Y Target Price 168.25 |
Price to earnings Ratio - | 1Y Target Price 168.25 | ||
Volume (30-day avg) 2.9M shares | Beta 2.22 | 52 Weeks Range 23.30 - 219.71 | Updated Date 11/08/2026 |
52 Weeks Range 23.30 - 219.71 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Synthetic Biology | Custom genes, oligo pools, and DNA libraries for academic and corporate R&D. | Selling the 'building blocks' of biology to researchers who are engineering cells or drugs. |
| NGS Tools | Library prep kits and target enrichment panels for sequencing workflows. | Providing essential supplies that enable scientists to analyze genomic data accurately. |
| Biopharma Services | Antibody discovery and protein engineering services. | Partnering with pharma companies to help them identify potential new drug candidates. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7.94B | Price to Sales(TTM) 18.55 |
Enterprise Value 7.94B | Price to Sales(TTM) 18.55 | ||
Enterprise Value to Revenue 18.4 | Enterprise Value to EBITDA -35.26 | Shares Outstanding 66.30M | Shares Floating 61.88M |
Shares Outstanding 66.30M | Shares Floating 61.88M | ||
Percent Insiders 0.9 | Percent Institutions 114.67 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.